Vertex's CRISPR Therapy Casgevy Shows Promise in Children as Young as 5 with Blood Disorders
Key Insights
Vertex Pharmaceuticals' CRISPR gene therapy Casgevy successfully prevented painful vaso-occlusive crises in children aged 5-11 with sickle cell disease (search) for at least 12 consecutive months.
The therapy enabled children with beta thalassemia (search) to remain transfusion-free for up to nearly two years, marking the first clinical data for genetic therapy in this young age group.
Vertex plans to file for regulatory approval in the first half of 2026, with the FDA granting a national priority review voucher that could accelerate approval to just 1-2 months.
Vertex Pharmaceuticals' groundbreaking CRISPR gene therapy Casgevy has demonstrated significant efficacy in treating children as young as 5 years old with severe blood disorders, according to data presented at the American Society of Hematology (search) scientific meeting in Orlando. The results mark the first clinical data ever presented on genetic therapy for children ages 5-11 years with sickle cell disease (search) and could help expand the commercial reach of the world's first approved CRISPR therapeutic.
Strong Efficacy in Sickle Cell Disease
In the sickle cell disease (search) trial, all four children who completed at least one year of follow-up remained free of vaso-occlusive crises for 12 consecutive months after receiving Casgevy treatment. These painful episodes, caused by blockages of blood vessels by sickled red blood cells, represent a key hallmark of the inherited blood disorder and result in severe, debilitating pain. One patient has maintained crisis-free status for nearly two years, and notably, no patient in the 11-child trial has experienced a vaso-occlusive crisis to date.
"I am excited to hopefully be able to offer this option to my younger patients soon, early in life, before some of the most devastating impacts of these diseases begin," said Haydar Frangoul, a trial investigator and medical director of pediatric hematology and oncology at Sarah Cannon Research Institute (search).
Beta Thalassemia Results Show Transfusion Independence
The beta thalassemia (search) trial enrolled 13 children who previously depended on regular blood transfusions to maintain target hemoglobin levels. Of the six patients followed for sufficient duration, all achieved the trial's primary endpoint of remaining transfusion-free for at least 12 consecutive months. The longest period of transfusion independence reached nearly two years.
However, the trial experienced one fatality when a patient died from pneumonia (search) and multi-organ failure due to severe veno-occlusive disease (search), a liver condition related to the preconditioning treatment using the chemotherapy drug busulfan that weakens the immune system before cell infusion.
Accelerated Regulatory Pathway
Casgevy has received a Commissioner's National Priority Voucher from the FDA for the 5-11 year age group under a program instituted by FDA Commissioner Martin Makary. This designation could shorten the review period to just one or two months, making it one of 15 drugs awarded this accelerated review status. Vertex plans to file for approval in this younger patient population during the first half of 2026.
CRISPR Technology and Mechanism
Casgevy utilizes Nobel Prize-winning CRISPR gene editing technology, employing molecular "scissors" to modify faulty genes. The therapy is manufactured from patients' own bone marrow cells, which are genetically engineered to stimulate production of fetal hemoglobin (search). In sickle cell disease (search), this protein prevents the characteristic cell bending that causes vessel blockages, while in beta thalassemia (search), it helps prevent anemia and reduces transfusion requirements.
Commercial Implications
Despite being hailed as a potentially permanent treatment when it gained approval, Casgevy has generated modest commercial returns since its launch two years ago. Vertex has recorded approximately $43 million in revenue from the therapy, though company executives project it could reach $100 million this year. The expansion into younger patient populations could significantly broaden the therapy's market potential.
"These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the transformative potential of Casgevy," said Carmen Bozic, Vertex's Chief Medical Officer.